Interface Biologics Expands Scientific Advisory Board
Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today the appointment of Dr. John Denstedt, Dr. Curtis Nickel and Dr. Leonard Pinchuk to its Scientific Advisory Boar

Toronto, Canada, October 19, 2009 – For Immediate Release

Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today the appointment of Dr. John Denstedt, Dr. Curtis Nickel and Dr. Leonard Pinchuk to its Scientific Advisory Board ("SAB").

These appointments further strengthen the board of world renowned scientists and clinicians that includes Prof. J. Paul Santerre, (Professor of Biomaterials and Director of the Institute of Biomaterials and Biomedical Engineering at the University of Toronto), Dr. Nicolas Chronos(interventional cardiologist and CEO of the St. Joseph’s Translational Research Institute, Atlanta GA), Dr. Tony Khoury (Chief of Pediatric Urology at Children’s Hospital of Orange County and University of California Irvine Medical Center), Prof. Rosalind Labow (Professor of Surgery and Biochemistry, University of Ottawa, and Director, Taichman Laboratory, University of Ottawa Heart Institute), Prof. Marc W. Mittelman (Professor of Microbiology, Bristol College, Boston, MA), Dr. Robert Schwartz(Professor of Medicine, University of Minnesota, and Medical Director, Minneapolis Heart Institute Foundation), and Dr. Bradley Strauss(Professor of Medicine, University of Toronto; Director, interventional cardiology research, Sunnybrook Health Sciences Centre, Toronto ON).

Dr. Denstedt is Professor of Urology and Chairman of the Department of Surgery at The University of Western Ontario. He is the author of over 200 scientific articles and book chapters and has been guest professor at over 200 universities, national meetings and instructional courses throughout the world. In 1997 he received the Gold Cystoscope Award - one of the highest honours in the American Urological Association. His clinical practice is primarily in endourology with research interests in urolithiasis, biofilms, lasers and minimally invasive techniques in urology.

Dr. Nickel is Professor of Urology at Queen’s University in Kingston, Ontario. He is renowned for his research in the fields of inflammatory diseases of the urinary tract and benign diseases of the prostate gland. He has written over 375 scientific papers, reviews, chapters and books on these subjects. His work in prostatitis has led to updated definitions and classifications, validated outcome parameters and recently, multiple clinical treatment trials in this difficult field. In November 2007 he was awarded the prestigious Canada Institute for Health Research Tier 1 Canada Research Chair in Urologic Pain and Inflammation.

Dr. Pinchuk is an inventor and entrepreneur in the field of biomaterials and medical devices with over 80 patents in this area. In addition to founding or co-founding five start-up companies, his accomplishments include the invention of the nylon angioplasty balloon, the world’s most widely used angioplasty catheter; a family of polycarbonate urethane biomaterials for implantation applications; polyurethane-based vascular grafts and stent-grafts; and the use of the novel biomaterial “SIBS” for long-term implantation applications. These SIBS formulations have contributed to the development and success of several implantable devices.

The expanded SAB met in Toronto earlier this month to discuss IBI’s research and development, and early commercialization activities. The SAB provides critical advice to IBI development and marketing teams to ensure that application of IBI’s advanced polymer technologies fulfill unmet medical and commercial needs.

"We are delighted to have these eminent clinicians and scientists on our advisory board” said Thomas P. Reeves, President and CEO, Interface Biologics. “IBI has an outstanding group of scientific advisors who bring complementary skills and experience to our development and commercialization programs.”

Dr. Tony Khoury expressed delight with recent IBI progress. “The next few years will be very exciting at Interface Biologics. We, as clinicians, look forward to the day when medical device related thrombosis and infection, can be eliminated.”

About Interface Biologics Inc.

Interface Biologics develops technologies that work at the molecular level of the patient-device interface to enhance the safety and effectiveness of implantable medical devices through inhibition of thrombosis, infection control and unique, programmable delivery of pharmaceuticals and biologics. Interface has three product families: Endexo? Anti-thrombogenic Additives, Epidel? Anti-infective Polymers and Kinesyx? Bioactive Oligomers, all of which have applications across a broad spectrum of implantable medical devices.

Julie Fotheringham
Partner, Hageman Communications

Powered by Innovasium